Sun Pharma, India's largest drugmaker, is set to acquire the remaining 21.52% stake in Israel-based Taro Pharmaceutical Industries for ₹2,8...

The move could be a booster for Sun Pharma shares as corporate governance issues have weighed investor sentiment for the past two years.

The firm's whole-time directors - Sudhir V Valia and Sailesh T Desai - paid Rs 37.41 lakh each, and Kalyanasundaram Subramanian had to remi...

Sebi had initiated a probe against Sun Pharma, its managing director Dilip Shanghvi and its directors on the basis of two whistleblower com...

The company, last Thursday, announced the acquisition of an oncology product for launch in global mar kets. This is the company's third acq...

Baldota, who has also been nominated to Taro's board of directors, is expected to begin his role as CEO on or about April 1, 2017, and will...

The sprawling site has been blocked by the US Food and Drug Administration since 2008 following revelations of manipulation of data.

The stock has fallen on reports that Halol plant in Gujarat has been subjected to surprise inspection by the American drug regulator USFDA.

This is the third such recall for Sun which agreed to buy troubled fellow drug maker Ranbaxy in March this year to create the world's fifth...

Sun and their Japanese counterparts met for the first time as recently as the third week of March. A final agreement was in place by the en...

Mumbai-based Sun Pharma will not revise its offer price to minority shareholders of Isreali drug maker Taro pharma, a company official said.

Guggenheim Partners offered to buy Sun Pharmaceutical Industries’ stake in Taro Pharmaceuticals Industries on behalf of clients for about $...

Eli Lilly sued India's Sun Pharmaceutical Industries to prevent it from selling a generic version of the hyperactivity-disorder drug Stratt...

Sun Pharmaceuticals has prepared a war chest of $500 million for acquisitions in the US, as it bets big on the world's largest drugs market.